Share Price and Basic Stock Data
Last Updated: October 18, 2025, 5:43 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Krebs Biochemicals & Industries Ltd operates within the pharmaceuticals sector, with its share price currently at ₹71.4 and a market capitalization of ₹153 Cr. The company has shown fluctuating sales figures, reporting ₹10.64 Cr in June 2022, peaking at ₹20.94 Cr in September 2022 before declining to ₹9.09 Cr in December 2022. The sales trend remained unstable, with recent figures showing ₹14.89 Cr in September 2023 and ₹12.98 Cr in December 2023, indicating a volatile revenue generation pattern. Year-on-year, sales are projected to decline, with ₹50 Cr in FY 2024 and further down to ₹43 Cr in FY 2025. This inconsistent revenue performance raises concerns about the company’s market positioning and operational efficiency. The cost structure is also a concern, as total expenses have been high, resulting in negative operating profits across several quarters. The operating profit margin (OPM) stood at a troubling -38.14%, reflecting the need for effective cost management strategies to stabilize revenue streams.
Profitability and Efficiency Metrics
Krebs Biochemicals has consistently reported negative profitability metrics, with a net profit of -₹27 Cr for the latest fiscal year. The operating profit margins have been significantly low, peaking at -58.93% in June 2022 and fluctuating around -30% to -41% in subsequent periods. The interest coverage ratio (ICR) stands at 1.76x, indicating that the company struggles to cover its interest expenses adequately, which is concerning for creditors and investors alike. This financial strain is compounded by a cash conversion cycle of -795 days, highlighting inefficiencies in managing working capital. Debtor days and inventory turnover ratios have also shown signs of inefficiency, with debtor days averaging 4 in recent quarters and inventory days rising to 543 in March 2024. These inefficiencies suggest that the company may face challenges in maintaining liquidity and operational agility, which could hinder its ability to capitalize on market opportunities.
Balance Sheet Strength and Financial Ratios
The balance sheet of Krebs Biochemicals reveals a concerning financial situation, with total borrowings reported at ₹212 Cr against negative reserves of ₹168 Cr. The debt-to-equity ratio stands at -0.53, indicating a high reliance on debt financing relative to equity, a risky position for any company. The current ratio is low at 0.28, suggesting liquidity issues that could affect short-term operational capabilities. Furthermore, the company has an interest coverage ratio of -1.76, indicating that it is unable to generate sufficient earnings to cover its interest obligations. The book value per share is negative at -₹55.29, reflecting a lack of retained earnings and a deteriorating equity position. The financial ratios indicate a company that is under significant financial pressure, which may deter potential investors and limit access to further financing.
Shareholding Pattern and Investor Confidence
Krebs Biochemicals has a concentrated shareholding structure, with promoters holding 72.74% of the equity. This high level of promoter ownership suggests a strong commitment from the founding members, which can instill confidence among investors. However, foreign institutional investors (FIIs) hold a mere 0.50%, indicating limited external interest in the company, which could be a red flag for potential investors. The number of shareholders has seen a decline, from 9,650 in September 2022 to 9,118 in June 2025, reflecting waning investor confidence. The public shareholding stands at 26.76%, which is more stable but still indicates a lack of broader market participation. This combination of high promoter control and low institutional interest may limit the company’s growth prospects and its ability to attract further investment.
Outlook, Risks, and Final Insight
If margins sustain their current trajectory of significant losses, the company may face increased scrutiny from investors and creditors, leading to potential liquidity challenges. The persistent negative net profit and declining sales figures indicate that Krebs Biochemicals must implement robust strategies to improve operational efficiency and profitability. Addressing the high cash conversion cycle and enhancing inventory turnover will be critical for stabilizing cash flows. Additionally, if the company can manage its debt levels effectively and improve its interest coverage, it could enhance its financial stability. However, the risks associated with high debt, negative reserves, and limited investor interest present substantial challenges. Thus, the path forward requires diligent management and strategic operational changes to foster recovery and growth in an increasingly competitive pharmaceutical landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Krebs Biochemicals & Industries Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 148 Cr. | 117 | 247/84.3 | 33.6 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.96 Cr. | 2.07 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,702 Cr. | 432 | 440/192 | 105 | 22.8 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 36.4 Cr. | 49.0 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 30.0 Cr. | 20.4 | 29.1/17.0 | 31.2 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,828.94 Cr | 1,185.68 | 50.47 | 194.07 | 0.34% | 16.24% | 14.95% | 6.10 |
All Competitor Stocks of Krebs Biochemicals & Industries Ltd
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 10.64 | 20.94 | 9.09 | 11.46 | 10.58 | 14.89 | 12.98 | 11.97 | 12.89 | 12.86 | 11.47 | 6.10 | 5.48 |
| Expenses | 16.91 | 22.84 | 12.07 | 16.08 | 13.20 | 15.79 | 15.07 | 15.09 | 15.08 | 15.58 | 16.18 | 11.51 | 7.57 |
| Operating Profit | -6.27 | -1.90 | -2.98 | -4.62 | -2.62 | -0.90 | -2.09 | -3.12 | -2.19 | -2.72 | -4.71 | -5.41 | -2.09 |
| OPM % | -58.93% | -9.07% | -32.78% | -40.31% | -24.76% | -6.04% | -16.10% | -26.07% | -16.99% | -21.15% | -41.06% | -88.69% | -38.14% |
| Other Income | 0.13 | 0.27 | 0.02 | 0.19 | 0.04 | 0.17 | 0.03 | 0.21 | 0.03 | 0.09 | 0.25 | 0.34 | 0.01 |
| Interest | 0.30 | 0.74 | 0.90 | 1.03 | 1.10 | 1.13 | 1.19 | 1.27 | 1.32 | 1.42 | 1.56 | 1.61 | 1.65 |
| Depreciation | 1.69 | 1.69 | 1.69 | 1.48 | 1.65 | 1.71 | 1.73 | 1.67 | 1.69 | 1.71 | 1.72 | 1.57 | 1.60 |
| Profit before tax | -8.13 | -4.06 | -5.55 | -6.94 | -5.33 | -3.57 | -4.98 | -5.85 | -5.17 | -5.76 | -7.74 | -8.25 | -5.33 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.24% | 0.00% |
| Net Profit | -8.14 | -4.06 | -5.55 | -6.94 | -5.33 | -3.57 | -4.98 | -5.85 | -5.17 | -5.76 | -7.74 | -8.27 | -5.32 |
| EPS in Rs | -3.78 | -1.88 | -2.57 | -3.22 | -2.47 | -1.66 | -2.31 | -2.71 | -2.40 | -2.67 | -3.59 | -3.84 | -2.47 |
Last Updated: August 20, 2025, 8:00 am
Below is a detailed analysis of the quarterly data for Krebs Biochemicals & Industries Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 5.48 Cr.. The value appears to be declining and may need further review. It has decreased from 6.10 Cr. (Mar 2025) to 5.48 Cr., marking a decrease of 0.62 Cr..
- For Expenses, as of Jun 2025, the value is 7.57 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 11.51 Cr. (Mar 2025) to 7.57 Cr., marking a decrease of 3.94 Cr..
- For Operating Profit, as of Jun 2025, the value is -2.09 Cr.. The value appears strong and on an upward trend. It has increased from -5.41 Cr. (Mar 2025) to -2.09 Cr., marking an increase of 3.32 Cr..
- For OPM %, as of Jun 2025, the value is -38.14%. The value appears strong and on an upward trend. It has increased from -88.69% (Mar 2025) to -38.14%, marking an increase of 50.55%.
- For Other Income, as of Jun 2025, the value is 0.01 Cr.. The value appears to be declining and may need further review. It has decreased from 0.34 Cr. (Mar 2025) to 0.01 Cr., marking a decrease of 0.33 Cr..
- For Interest, as of Jun 2025, the value is 1.65 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.61 Cr. (Mar 2025) to 1.65 Cr., marking an increase of 0.04 Cr..
- For Depreciation, as of Jun 2025, the value is 1.60 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.57 Cr. (Mar 2025) to 1.60 Cr., marking an increase of 0.03 Cr..
- For Profit before tax, as of Jun 2025, the value is -5.33 Cr.. The value appears strong and on an upward trend. It has increased from -8.25 Cr. (Mar 2025) to -5.33 Cr., marking an increase of 2.92 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value appears to be improving (decreasing) as expected. It has decreased from 0.24% (Mar 2025) to 0.00%, marking a decrease of 0.24%.
- For Net Profit, as of Jun 2025, the value is -5.32 Cr.. The value appears strong and on an upward trend. It has increased from -8.27 Cr. (Mar 2025) to -5.32 Cr., marking an increase of 2.95 Cr..
- For EPS in Rs, as of Jun 2025, the value is -2.47. The value appears strong and on an upward trend. It has increased from -3.84 (Mar 2025) to -2.47, marking an increase of 1.37.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:58 am
| Metric | Sep 2014n n 15m | Mar 2015n n 6m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 1 | 3 | 34 | 48 | 33 | 54 | 60 | 52 | 50 | 43 | 36 |
| Expenses | 4 | 5 | 14 | 11 | 41 | 58 | 52 | 71 | 94 | 68 | 59 | 58 | 51 |
| Operating Profit | -4 | -5 | -12 | -8 | -8 | -10 | -19 | -18 | -34 | -16 | -9 | -15 | -15 |
| OPM % | -1,088% | -248% | -22% | -20% | -56% | -33% | -57% | -30% | -17% | -35% | -42% | ||
| Other Income | 0 | 3 | 1 | -0 | -1 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 1 |
| Interest | 0 | 4 | 1 | 3 | 5 | 6 | 6 | 6 | 5 | 3 | 5 | 6 | 6 |
| Depreciation | 0 | 2 | 4 | 4 | 4 | 4 | 5 | 5 | 6 | 7 | 7 | 7 | 7 |
| Profit before tax | -4 | -8 | -16 | -16 | -18 | -20 | -29 | -28 | -45 | -25 | -20 | -27 | -27 |
| Tax % | 10% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | |
| Net Profit | -4 | -8 | -16 | -16 | -18 | -20 | -29 | -28 | -45 | -25 | -20 | -27 | -27 |
| EPS in Rs | -3.78 | -6.82 | -10.33 | -9.67 | -10.73 | -12.03 | -16.04 | -14.45 | -20.65 | -11.45 | -9.15 | -12.50 | -12.57 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | -12.50% | -11.11% | -45.00% | 3.45% | -60.71% | 44.44% | 20.00% | -35.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -12.50% | 1.39% | -33.89% | 48.45% | -64.16% | 105.16% | -24.44% | -55.00% |
Krebs Biochemicals & Industries Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2016-2017 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 5% |
| 3 Years: | -10% |
| TTM: | -32% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 1% |
| 3 Years: | 12% |
| TTM: | -38% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | -4% |
| 3 Years: | -19% |
| 1 Year: | -15% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Last Updated: September 5, 2025, 9:20 am
Balance Sheet
Last Updated: September 10, 2025, 1:58 pm
| Month | Sep 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 13 | 14 | 14 | 17 | 18 | 20 | 22 | 22 | 22 | 22 |
| Reserves | -6 | 9 | -0 | -12 | -32 | -31 | -43 | -62 | -97 | -121 | -141 | -168 |
| Borrowings | 93 | 61 | 31 | 48 | 56 | 53 | 66 | 111 | 143 | 183 | 194 | 212 |
| Other Liabilities | 41 | 29 | 73 | 73 | 87 | 103 | 93 | 91 | 122 | 91 | 104 | 103 |
| Total Liabilities | 138 | 108 | 116 | 122 | 126 | 142 | 134 | 159 | 190 | 175 | 178 | 169 |
| Fixed Assets | 58 | 58 | 93 | 102 | 101 | 101 | 105 | 118 | 139 | 147 | 150 | 146 |
| CWIP | 0 | 0 | 11 | 4 | 4 | 3 | 4 | 12 | 8 | 4 | 2 | 3 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 80 | 50 | 13 | 16 | 21 | 38 | 24 | 29 | 43 | 24 | 26 | 20 |
| Total Assets | 138 | 108 | 116 | 122 | 126 | 142 | 134 | 159 | 190 | 175 | 178 | 169 |
Below is a detailed analysis of the balance sheet data for Krebs Biochemicals & Industries Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 22.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 22.00 Cr..
- For Reserves, as of Mar 2025, the value is -168.00 Cr.. The value appears to be worsening (becoming more negative). It has deteriorated from -141.00 Cr. (Mar 2024) to -168.00 Cr., marking a decline of 27.00 Cr..
- For Borrowings, as of Mar 2025, the value is 212.00 Cr.. The value appears to be increasing, which may not be favorable. However, Reserves are negative, which is a major warning sign. It has increased from 194.00 Cr. (Mar 2024) to 212.00 Cr., marking an increase of 18.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 103.00 Cr.. The value appears to be improving (decreasing). It has decreased from 104.00 Cr. (Mar 2024) to 103.00 Cr., marking a decrease of 1.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 169.00 Cr.. The value appears to be improving (decreasing). It has decreased from 178.00 Cr. (Mar 2024) to 169.00 Cr., marking a decrease of 9.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 146.00 Cr.. The value appears to be declining and may need further review. It has decreased from 150.00 Cr. (Mar 2024) to 146.00 Cr., marking a decrease of 4.00 Cr..
- For CWIP, as of Mar 2025, the value is 3.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Mar 2024) to 3.00 Cr., marking an increase of 1.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 20.00 Cr.. The value appears to be declining and may need further review. It has decreased from 26.00 Cr. (Mar 2024) to 20.00 Cr., marking a decrease of 6.00 Cr..
- For Total Assets, as of Mar 2025, the value is 169.00 Cr.. The value appears to be declining and may need further review. It has decreased from 178.00 Cr. (Mar 2024) to 169.00 Cr., marking a decrease of 9.00 Cr..
However, the Borrowings (212.00 Cr.) are higher than the Reserves (-168.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2015n n 6m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2014n n 15m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -5.00 | -43.00 | -56.00 | -64.00 | -63.00 | -85.00 | -129.00 | -177.00 | -199.00 | -203.00 | -227.00 | -4.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Sep 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 10 | 180 | 3 | 22 | 2 | 2 | 5 | 4 | 14 | 0 | ||
| Inventory Days | 14,704 | 2,162 | 337 | 142 | 345 | 234 | 230 | 170 | 543 | 396 | ||
| Days Payable | 32,250 | 4,360 | 510 | 339 | 521 | 292 | 340 | 217 | 1,051 | 1,192 | ||
| Cash Conversion Cycle | -17,536 | -2,018 | -170 | -175 | -174 | -57 | -106 | -44 | -494 | -795 | ||
| Working Capital Days | -6,532 | -2,132 | -275 | -315 | -267 | -187 | -261 | -232 | -322 | -787 | ||
| ROCE % | -4% | -8% | -26% | -26% | -26% | -36% | -57% | -40% | -57% | -29% | -19% | -30% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -12.49 | -9.16 | -11.30 | -20.81 | -14.53 |
| Diluted EPS (Rs.) | -12.49 | -9.16 | -11.30 | -20.81 | -14.53 |
| Cash EPS (Rs.) | -9.39 | -6.01 | -8.41 | -17.73 | -11.84 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | -67.83 | -55.29 | -46.13 | -34.83 | -21.78 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | -67.83 | -55.29 | -46.13 | -34.83 | -21.78 |
| Revenue From Operations / Share (Rs.) | 20.09 | 23.39 | 24.18 | 27.69 | 27.37 |
| PBDIT / Share (Rs.) | -6.64 | -3.84 | -7.03 | -15.23 | -8.64 |
| PBIT / Share (Rs.) | -9.74 | -6.97 | -10.07 | -18.15 | -11.25 |
| PBT / Share (Rs.) | -12.49 | -9.15 | -11.45 | -20.65 | -14.45 |
| Net Profit / Share (Rs.) | -12.49 | -9.15 | -11.45 | -20.65 | -14.45 |
| PBDIT Margin (%) | -33.06 | -16.40 | -29.07 | -55.00 | -31.57 |
| PBIT Margin (%) | -48.50 | -29.82 | -41.65 | -65.55 | -41.11 |
| PBT Margin (%) | -62.16 | -39.12 | -47.36 | -74.58 | -52.80 |
| Net Profit Margin (%) | -62.19 | -39.12 | -47.36 | -74.58 | -52.80 |
| Return on Capital Employeed (%) | -32.07 | -12.92 | -17.25 | -35.02 | -19.88 |
| Return On Assets (%) | -15.93 | -11.07 | -14.11 | -23.45 | -17.81 |
| Long Term Debt / Equity (X) | -0.21 | -0.44 | -0.43 | -0.03 | -2.35 |
| Total Debt / Equity (X) | -0.56 | -0.53 | -0.53 | -0.17 | -2.35 |
| Asset Turnover Ratio (%) | 0.24 | 0.28 | 0.28 | 0.34 | 0.36 |
| Current Ratio (X) | 0.09 | 0.28 | 0.32 | 0.45 | 0.44 |
| Quick Ratio (X) | 0.04 | 0.12 | 0.08 | 0.12 | 0.09 |
| Inventory Turnover Ratio (X) | 5.47 | 0.49 | 0.81 | 2.19 | 1.62 |
| Interest Coverage Ratio (X) | -2.42 | -1.76 | -5.10 | -6.09 | -2.70 |
| Interest Coverage Ratio (Post Tax) (X) | -3.56 | -3.21 | -7.30 | -7.26 | -3.52 |
| Enterprise Value (Cr.) | 356.07 | 324.85 | 304.75 | 451.99 | 274.16 |
| EV / Net Operating Revenue (X) | 8.22 | 6.44 | 5.85 | 7.57 | 5.11 |
| EV / EBITDA (X) | -24.86 | -39.27 | -20.10 | -13.76 | -16.17 |
| MarketCap / Net Operating Revenue (X) | 3.32 | 2.61 | 2.33 | 5.18 | 3.25 |
| Price / BV (X) | -0.98 | -1.10 | -1.22 | -4.12 | -4.08 |
| Price / Net Operating Revenue (X) | 3.32 | 2.61 | 2.33 | 5.18 | 3.25 |
| EarningsYield | -0.18 | -0.14 | -0.20 | -0.14 | -0.16 |
After reviewing the key financial ratios for Krebs Biochemicals & Industries Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -12.49. This value is below the healthy minimum of 5. It has decreased from -9.16 (Mar 24) to -12.49, marking a decrease of 3.33.
- For Diluted EPS (Rs.), as of Mar 25, the value is -12.49. This value is below the healthy minimum of 5. It has decreased from -9.16 (Mar 24) to -12.49, marking a decrease of 3.33.
- For Cash EPS (Rs.), as of Mar 25, the value is -9.39. This value is below the healthy minimum of 3. It has decreased from -6.01 (Mar 24) to -9.39, marking a decrease of 3.38.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is -67.83. It has decreased from -55.29 (Mar 24) to -67.83, marking a decrease of 12.54.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is -67.83. It has decreased from -55.29 (Mar 24) to -67.83, marking a decrease of 12.54.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 20.09. It has decreased from 23.39 (Mar 24) to 20.09, marking a decrease of 3.30.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -6.64. This value is below the healthy minimum of 2. It has decreased from -3.84 (Mar 24) to -6.64, marking a decrease of 2.80.
- For PBIT / Share (Rs.), as of Mar 25, the value is -9.74. This value is below the healthy minimum of 0. It has decreased from -6.97 (Mar 24) to -9.74, marking a decrease of 2.77.
- For PBT / Share (Rs.), as of Mar 25, the value is -12.49. This value is below the healthy minimum of 0. It has decreased from -9.15 (Mar 24) to -12.49, marking a decrease of 3.34.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -12.49. This value is below the healthy minimum of 2. It has decreased from -9.15 (Mar 24) to -12.49, marking a decrease of 3.34.
- For PBDIT Margin (%), as of Mar 25, the value is -33.06. This value is below the healthy minimum of 10. It has decreased from -16.40 (Mar 24) to -33.06, marking a decrease of 16.66.
- For PBIT Margin (%), as of Mar 25, the value is -48.50. This value is below the healthy minimum of 10. It has decreased from -29.82 (Mar 24) to -48.50, marking a decrease of 18.68.
- For PBT Margin (%), as of Mar 25, the value is -62.16. This value is below the healthy minimum of 10. It has decreased from -39.12 (Mar 24) to -62.16, marking a decrease of 23.04.
- For Net Profit Margin (%), as of Mar 25, the value is -62.19. This value is below the healthy minimum of 5. It has decreased from -39.12 (Mar 24) to -62.19, marking a decrease of 23.07.
- For Return on Capital Employeed (%), as of Mar 25, the value is -32.07. This value is below the healthy minimum of 10. It has decreased from -12.92 (Mar 24) to -32.07, marking a decrease of 19.15.
- For Return On Assets (%), as of Mar 25, the value is -15.93. This value is below the healthy minimum of 5. It has decreased from -11.07 (Mar 24) to -15.93, marking a decrease of 4.86.
- For Long Term Debt / Equity (X), as of Mar 25, the value is -0.21. This value is below the healthy minimum of 0.2. It has increased from -0.44 (Mar 24) to -0.21, marking an increase of 0.23.
- For Total Debt / Equity (X), as of Mar 25, the value is -0.56. This value is within the healthy range. It has decreased from -0.53 (Mar 24) to -0.56, marking a decrease of 0.03.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.24. It has decreased from 0.28 (Mar 24) to 0.24, marking a decrease of 0.04.
- For Current Ratio (X), as of Mar 25, the value is 0.09. This value is below the healthy minimum of 1.5. It has decreased from 0.28 (Mar 24) to 0.09, marking a decrease of 0.19.
- For Quick Ratio (X), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 1. It has decreased from 0.12 (Mar 24) to 0.04, marking a decrease of 0.08.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.47. This value is within the healthy range. It has increased from 0.49 (Mar 24) to 5.47, marking an increase of 4.98.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -2.42. This value is below the healthy minimum of 3. It has decreased from -1.76 (Mar 24) to -2.42, marking a decrease of 0.66.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -3.56. This value is below the healthy minimum of 3. It has decreased from -3.21 (Mar 24) to -3.56, marking a decrease of 0.35.
- For Enterprise Value (Cr.), as of Mar 25, the value is 356.07. It has increased from 324.85 (Mar 24) to 356.07, marking an increase of 31.22.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 8.22. This value exceeds the healthy maximum of 3. It has increased from 6.44 (Mar 24) to 8.22, marking an increase of 1.78.
- For EV / EBITDA (X), as of Mar 25, the value is -24.86. This value is below the healthy minimum of 5. It has increased from -39.27 (Mar 24) to -24.86, marking an increase of 14.41.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.32. This value exceeds the healthy maximum of 3. It has increased from 2.61 (Mar 24) to 3.32, marking an increase of 0.71.
- For Price / BV (X), as of Mar 25, the value is -0.98. This value is below the healthy minimum of 1. It has increased from -1.10 (Mar 24) to -0.98, marking an increase of 0.12.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.32. This value exceeds the healthy maximum of 3. It has increased from 2.61 (Mar 24) to 3.32, marking an increase of 0.71.
- For EarningsYield, as of Mar 25, the value is -0.18. This value is below the healthy minimum of 5. It has decreased from -0.14 (Mar 24) to -0.18, marking a decrease of 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Krebs Biochemicals & Industries Ltd:
- Net Profit Margin: -62.19%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -32.07% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -3.56
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.04
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 50.47)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: -0.56
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -62.19%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Kothapalli Village, Kasimkota Mandal, Anakapalli Dist. Andhra Pradesh 531031 | investors@krebsbiochem.com www.krebsbiochem.com |
| Management | |
|---|---|
| Name | Position Held |
| Dr. R T Ravi | Chairman & Non-Exe.Director |
| Mr. Manish Kumar Jain | Managing Director & CEO |
| Mr. P K Bhattacharyya | Non Executive Director |
| Mr. Avinash Ravi | Non Executive Director |
| Mr. P M Kathariya | Independent Director |
| Ms. Dipti Shah | Independent Director |
| Mr. Satya Prakash Chigurupati | Independent Director |
| Mr. Sumanth Karlapudi | Independent Director |
FAQ
What is the intrinsic value of Krebs Biochemicals & Industries Ltd?
Krebs Biochemicals & Industries Ltd's intrinsic value (as of 18 October 2025) is 124.48 which is 78.85% higher the current market price of 69.60, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 150 Cr. market cap, FY2025-2026 high/low of 129/63.6, reserves of ₹-168 Cr, and liabilities of 169 Cr.
What is the Market Cap of Krebs Biochemicals & Industries Ltd?
The Market Cap of Krebs Biochemicals & Industries Ltd is 150 Cr..
What is the current Stock Price of Krebs Biochemicals & Industries Ltd as on 18 October 2025?
The current stock price of Krebs Biochemicals & Industries Ltd as on 18 October 2025 is 69.6.
What is the High / Low of Krebs Biochemicals & Industries Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Krebs Biochemicals & Industries Ltd stocks is 129/63.6.
What is the Stock P/E of Krebs Biochemicals & Industries Ltd?
The Stock P/E of Krebs Biochemicals & Industries Ltd is .
What is the Book Value of Krebs Biochemicals & Industries Ltd?
The Book Value of Krebs Biochemicals & Industries Ltd is 67.8.
What is the Dividend Yield of Krebs Biochemicals & Industries Ltd?
The Dividend Yield of Krebs Biochemicals & Industries Ltd is 0.00 %.
What is the ROCE of Krebs Biochemicals & Industries Ltd?
The ROCE of Krebs Biochemicals & Industries Ltd is 30.1 %.
What is the ROE of Krebs Biochemicals & Industries Ltd?
The ROE of Krebs Biochemicals & Industries Ltd is %.
What is the Face Value of Krebs Biochemicals & Industries Ltd?
The Face Value of Krebs Biochemicals & Industries Ltd is 10.0.